BioCryst Pharma (BCRX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
August 4, 2016 9:58 AM EDTJMP Securities downgraded BioCryst Pharma (NASDAQ: BCRX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $4.03 yesterday.
... More